Tipping William J, Tshuma Nkazimulo, Adams James, Haywood Harvey T, Rowedder James E, Fray M Jonathan, McInally Thomas, Macdonald Simon J F, Oldham Neil J
School of Chemistry, University of Nottingham , University Park, Nottingham NG7 2RD, U.K.
Fibrosis Discovery Performance Unit, GlaxoSmithKline, Medicines Research Centre , Gunnels Wood Road, Stevenage SG1 2NY, U.K.
ACS Med Chem Lett. 2014 Dec 22;6(2):221-4. doi: 10.1021/ml500395v. eCollection 2015 Feb 12.
The integrin αvβ6 is a potential target for treatment of idiopathic pulmonary fibrosis (IPF). Equilibrium dialysis (ED) was investigated for its ability to report ligand binding in an αvβ6 inhibitor screening assay. As a preliminary experiment, an established peptidomimetic inhibitor of the integrin was dialyzed against αvβ6, and the fraction bound (f b) and percentage saturation determined by liquid chromatography-mass spectrometry (LC-MS) analysis. Quantitation of the inhibitor in the two chambers of the ED cartridge revealed an uneven distribution in the presence of αvβ6, corresponding to near saturation binding to the protein (93 ± 3%), while the control (without integrin) showed an equal partitioning of the inhibitor on either side of the dialysis membrane. A competitive ED assay with a 12 component mixture of antagonists was conducted, and the results compared with an established cell adhesion assay for quantifying αvβ6 inhibition of individual antagonists. Compounds clustered into three groupings: those with pIC 50 values between ca. 5.0 and 5.5, which possessed ED f b values indistinguishable from the controls, those with pIC 50s of 6.5 ± 0.2, which exhibited detectable integrin binding (f b 13-25%) in the ED assay, and a single compound of pIC 50 7.2 possessing an f b value of 38%. A good correlation between ED-derived f b and pIC 50 was observed despite the two assays utilizing quite different outputs. These results demonstrate that ED with LC-MS detection shows promise as a rapid αvβ6 integrin antagonist screening assay for mixtures of putative ligands.
整合素αvβ6是特发性肺纤维化(IPF)治疗的潜在靶点。研究了平衡透析(ED)在αvβ6抑制剂筛选试验中报告配体结合的能力。作为初步实验,将一种已确立的整合素拟肽抑制剂与αvβ6进行透析,并通过液相色谱-质谱(LC-MS)分析确定结合分数(fb)和饱和百分比。对ED柱两个腔室中的抑制剂进行定量分析,结果显示在存在αvβ6的情况下分布不均,这与该蛋白的近乎饱和结合(93±3%)相对应,而对照组(无整合素)显示抑制剂在透析膜两侧均匀分布。进行了一项含有12种拮抗剂混合物的竞争性ED试验,并将结果与一种既定的细胞黏附试验进行比较,以量化αvβ6对各个拮抗剂的抑制作用。化合物分为三组:pIC50值在约5.0至5.5之间的化合物,其ED fb值与对照组无差异;pIC50为6.5±0.2的化合物,在ED试验中表现出可检测的整合素结合(fb为13 - 25%);以及一种pIC50为7.2的单一化合物,其fb值为38%。尽管两种试验使用的输出完全不同,但观察到ED衍生的fb与pIC50之间具有良好的相关性。这些结果表明,采用LC-MS检测的ED有望作为一种快速的αvβ6整合素拮抗剂筛选试验,用于筛选假定配体的混合物。